{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:48:27Z","timestamp":1774975707254,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202470"],"award-info":[{"award-number":["82202470"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172228"],"award-info":[{"award-number":["82172228"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102344"],"award-info":[{"award-number":["82102344"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR1019B"],"award-info":[{"award-number":["SHDC2020CR1019B"]}]},{"name":"Shanghai Clinical Research Center of Plastic and Reconstructive Surgery supported by Science and Technology Commission of Shanghai Municipality","award":["22MC1940300"],"award-info":[{"award-number":["22MC1940300"]}]},{"DOI":"10.13039\/100020732","name":"Innovative research team of high-level local universities in Shanghai","doi-asserted-by":"crossref","award":["SHSMU-ZDCX20210400"],"award-info":[{"award-number":["SHSMU-ZDCX20210400"]}],"id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Rising Star Program supported by Science and Technology Commission of Shanghai Municipality","award":["20QA1405600"],"award-info":[{"award-number":["20QA1405600"]}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["22ZR1422300"],"award-info":[{"award-number":["22ZR1422300"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13402-023-00819-4","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T13:02:01Z","timestamp":1682168521000},"page":"1399-1413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST"],"prefix":"10.1007","volume":"46","author":[{"given":"Man-Hon","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehanguli","family":"Aimaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zizhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manmei","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"key":"819_CR1","doi-asserted-by":"publisher","unstructured":"L.M.N. Wu, Y. Deng, J. Wang, C. Zhao, J. Wang, R. Rao, L. Xu, W. Zhou, K. Choi, T.A. Rizvi et al., Programming of Schwann cells by Lats1\/2-TAZ\/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell 33, (2018). https:\/\/doi.org\/10.1016\/j.ccell.2018.01.005","DOI":"10.1016\/j.ccell.2018.01.005"},{"key":"819_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00401-021-02341-z","volume":"142","author":"V Kochat","year":"2021","unstructured":"V. Kochat, A.T. Raman, S.M. Landers, M. Tang, J. Schulz, C. Terranova, J.P. Landry, A.D. Bhalla, H.C. Beird, C.-C. Wu et al., Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 142, 565\u2013590 (2021). https:\/\/doi.org\/10.1007\/s00401-021-02341-z","journal-title":"Acta Neuropathol."},{"key":"819_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3171\/2015.12.JNS152443","volume":"126","author":"KL Watson","year":"2017","unstructured":"K.L. Watson, G.A. Al Sannaa, C.M. Kivlin, D.R. Ingram, S.M. Landers, C.L. Roland, J.N. Cormier, K.K. Hunt, B.W. Feig, B. Ashleigh Guadagnolo et al., Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J. Neurosurg. 126, 319\u2013329 (2017). https:\/\/doi.org\/10.3171\/2015.12.JNS152443","journal-title":"J. Neurosurg."},{"key":"819_CR4","doi-asserted-by":"publisher","unstructured":"D.T. Miller, D. Freedenberg, E. Schorry, N.J. Ullrich, D. Viskochil and B.R. Korf, Health supervision for children with neurofibromatosis type 1. Pediatrics 143, (2019). https:\/\/doi.org\/10.1542\/peds.2019-0660","DOI":"10.1542\/peds.2019-0660"},{"key":"819_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11864-015-0328-6","volume":"16","author":"D Bradford","year":"2015","unstructured":"D. Bradford, A. Kim, Current treatment options for malignant peripheral nerve sheath tumors. Curr. Treat. Options Oncol. 16, 328 (2015). https:\/\/doi.org\/10.1007\/s11864-015-0328-6","journal-title":"Curr. Treat. Options Oncol."},{"key":"819_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11864-021-00830-7","volume":"22","author":"A Hassan","year":"2021","unstructured":"A. Hassan, R.C. Pestana, A. Parkes, Systemic options for malignant peripheral nerve sheath tumors. Curr. Treat. Options Oncol. 22, 33 (2021). https:\/\/doi.org\/10.1007\/s11864-021-00830-7","journal-title":"Curr. Treat. Options Oncol."},{"key":"819_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-biochem-013118-111843","volume":"89","author":"BL Greene","year":"2020","unstructured":"B.L. Greene, G. Kang, C. Cui, M. Bennati, D.G. Nocera, C.L. Drennan, J. Stubbe, Ribonucleotide reductases: structure, chemistry, and metabolism suggest new therapeutic targets. Annu. Rev. Biochem. 89, 45\u201375 (2020). https:\/\/doi.org\/10.1146\/annurev-biochem-013118-111843","journal-title":"Annu. Rev. Biochem."},{"key":"819_CR8","doi-asserted-by":"publisher","first-page":"32289","DOI":"10.1021\/acsami.0c06614","volume":"12","author":"M Zhang","year":"2020","unstructured":"M. Zhang, Y. Weng, Z. Cao, S. Guo, B. Hu, M. Lu, W. Guo, T. Yang, C. Li, X. Yang, Y. Huang, ROS-Activatable siRNA-Engineered Polyplex for NIR-Triggered synergistic cancer treatment. ACS Appl. Mater. Interfaces 12, 32289\u201332300 (2020). https:\/\/doi.org\/10.1021\/acsami.0c06614","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"819_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","volume":"149","author":"V D'Angiolella","year":"2012","unstructured":"V. D\u2019Angiolella, V. Donato, F.M. Forrester, Y.-T. Jeong, C. Pellacani, Y. Kudo, A. Saraf, L. Florens, M.P. Washburn, M. Pagano, Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 149, 1023\u20131034 (2012). https:\/\/doi.org\/10.1016\/j.cell.2012.03.043","journal-title":"Cell"},{"key":"819_CR10","doi-asserted-by":"publisher","first-page":"eabn1382","DOI":"10.1126\/sciadv.abn1382","volume":"8","author":"C Nunes","year":"2022","unstructured":"C. Nunes, L. Depestel, L. Mus, K.M. Keller, L. Delhaye, A. Louwagie, M. Rishfi, A. Whale, N. Kara, S.R. Andrews et al., RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. Sci. Adv. 8, eabn1382 (2022). https:\/\/doi.org\/10.1126\/sciadv.abn1382","journal-title":"Sci. Adv."},{"key":"819_CR11","doi-asserted-by":"publisher","first-page":"108872","DOI":"10.1016\/j.clim.2021.108872","volume":"232","author":"B Tang","year":"2021","unstructured":"B. Tang, W. Xu, Y. Wang, J. Zhu, H. Wang, J. Tu, Q. Weng, C. Kong, Y. Yang, R. Qiu, Z. Zhao, M. Xu, J. Ji, Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death. Clin. Immunol. 232, 108872 (2021). https:\/\/doi.org\/10.1016\/j.clim.2021.108872","journal-title":"Clin. Immunol."},{"key":"819_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41419-021-03969-1","volume":"12","author":"Q Liu","year":"2021","unstructured":"Q. Liu, L. Guo, H. Qi, M. Lou, R. Wang, B. Hai, K. Xu, L. Zhu, Y. Ding, C. Li, L. Xie, J. Shen, X. Xiang, J. Shao, A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer. Cell Death Dis. 12, 683 (2021). https:\/\/doi.org\/10.1038\/s41419-021-03969-1","journal-title":"Cell Death Dis."},{"key":"819_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-4598-10-15","volume":"10","author":"C Kretschmer","year":"2011","unstructured":"C. Kretschmer, A. Sterner-Kock, F. Siedentopf, W. Schoenegg, P.M. Schlag, W. Kemmner, Identification of early molecular markers for breast cancer. Mol. Cancer 10, 15 (2011). https:\/\/doi.org\/10.1186\/1476-4598-10-15","journal-title":"Mol. Cancer"},{"key":"819_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.omtn.2018.08.003","volume":"12","author":"S Zheng","year":"2018","unstructured":"S. Zheng, X. Wang, Y.-H. Weng, X. Jin, J.-L. Ji, L. Guo, B. Hu, N. Liu, Q. Cheng, J. Zhang, H. Bai, T. Yang, X.-H. Xia, H.-Y. Zhang, S. Gao, Y. Huang, siRNA knockdown of RRM2 effectively suppressed pancreatic tumor growth alone or synergistically with doxorubicin. Mol. Ther. Nucleic Acids 12, 805\u2013816 (2018). https:\/\/doi.org\/10.1016\/j.omtn.2018.08.003","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"819_CR15","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1158\/0008-5472.CAN-07-5873","volume":"68","author":"X Xu","year":"2008","unstructured":"X. Xu, J.L. Page, J.A. Surtees, H. Liu, S. Lagedrost, Y. Lu, R. Bronson, E. Alani, A.Y. Nikitin, R.S. Weiss, Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res. 68, 2652\u20132660 (2008). https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5873","journal-title":"Cancer Res."},{"key":"819_CR16","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1002\/jcp.26529","volume":"233","author":"C Li","year":"2018","unstructured":"C. Li, J. Zheng, S. Chen, B. Huang, G. Li, Z. Feng, J. Wang, S. Xu, RRM2 promotes the progression of human glioblastoma. J. Cell Physiol. 233, 6759\u20136767 (2018). https:\/\/doi.org\/10.1002\/jcp.26529","journal-title":"J. Cell Physiol."},{"key":"819_CR17","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-13-0073","volume":"19","author":"MA Rahman","year":"2013","unstructured":"M.A. Rahman, A.R.M.R. Amin, D. Wang, L. Koenig, S. Nannapaneni, Z. Chen, Z. Wang, G. Sica, X. Deng, Z.G. Chen, D.M. Shin, RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin. Cancer Res. 19, 3416\u20133428 (2013). https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0073","journal-title":"Clin. Cancer Res."},{"key":"819_CR18","doi-asserted-by":"publisher","unstructured":"S.E. Huff, J.M. Winter, C.G. Dealwis, Inhibitors of the cancer target ribonucleotide reductase, past and present. Biomolecules 12, (2022). https:\/\/doi.org\/10.3390\/biom12060815","DOI":"10.3390\/biom12060815"},{"key":"819_CR19","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"D. Szklarczyk, A.L. Gable, K.C. Nastou, D. Lyon, R. Kirsch, S. Pyysalo, N.T. Doncheva, M. Legeay, T. Fang, P. Bork, L.J. Jensen, C. von Mering, The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 49, D605\u2013D612 (2021). https:\/\/doi.org\/10.1093\/nar\/gkaa1074","journal-title":"Nucleic Acids Res."},{"key":"819_CR20","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, D. Ramage, N. Amin, B. Schwikowski, T. Ideker, Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003)","journal-title":"Genome Res."},{"key":"819_CR21","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8 Suppl 4","author":"C-H Chin","year":"2014","unstructured":"C.-H. Chin, S.-H. Chen, H.-H. Wu, C.-W. Ho, M.-T. Ko, C.-Y. Lin, cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8 Suppl 4, S11 (2014). https:\/\/doi.org\/10.1186\/1752-0509-8-S4-S11","journal-title":"BMC Syst. Biol."},{"key":"819_CR22","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzm\u00e1n","year":"2014","unstructured":"C. Guzm\u00e1n, M. Bagga, A. Kaur, J. Westermarck, D. Abankwa, ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One 9, e92444 (2014). https:\/\/doi.org\/10.1371\/journal.pone.0092444","journal-title":"PLoS One"},{"key":"819_CR23","doi-asserted-by":"publisher","DOI":"10.14806\/ej.17.1.200","author":"M Martin","year":"2011","unstructured":"M. Martin, Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal (2011). https:\/\/doi.org\/10.14806\/ej.17.1.200","journal-title":"EMBnet.journal"},{"key":"819_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"D. Kim, B. Langmead, S.L. Salzberg, HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015). https:\/\/doi.org\/10.1038\/nmeth.3317","journal-title":"Nat. Methods"},{"key":"819_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"M. Pertea, G.M. Pertea, C.M. Antonescu, T.-C. Chang, J.T. Mendell, S.L. Salzberg, StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290\u2013295 (2015). https:\/\/doi.org\/10.1038\/nbt.3122","journal-title":"Nat. Biotechnol."},{"key":"819_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"M.I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014)","journal-title":"Genome Biol."},{"key":"819_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1042\/CS20120240","volume":"124","author":"X Liu","year":"2013","unstructured":"X. Liu, H. Zhang, L. Lai, X. Wang, S. Loera, L. Xue, H. He, K. Zhang, S. Hu, Y. Huang, R.A. Nelson, B. Zhou, L. Zhou, P. Chu, S. Zhang, S. Zheng, Y. Yen, Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin. Sci. (Lond) 124, 567\u2013578 (2013). https:\/\/doi.org\/10.1042\/CS20120240","journal-title":"Clin. Sci. (Lond)"},{"key":"819_CR28","first-page":"2151","volume":"125","author":"L-M Wang","year":"2012","unstructured":"L.-M. Wang, F.-F. Lu, S.-Y. Zhang, R.-Y. Yao, X.-M. Xing, Z.-M. Wei, Overexpression of catalytic subunit M2 in patients with ovarian cancer. Chin. Med. J. (Engl) 125, 2151\u20132156 (2012)","journal-title":"Chin. Med. J. (Engl)"},{"key":"819_CR29","doi-asserted-by":"publisher","first-page":"i50","DOI":"10.1093\/noajnl\/vdz049","volume":"2","author":"A Pemov","year":"2020","unstructured":"A. Pemov, H. Li, W. Presley, M.R. Wallace, D.T. Miller, Genetics of human malignant peripheral nerve sheath tumors. Neurooncol. Adv. 2, i50\u2013i61 (2020). https:\/\/doi.org\/10.1093\/noajnl\/vdz049","journal-title":"Neurooncol. Adv."},{"key":"819_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/PAP.0000000000000197","volume":"25","author":"JF Longo","year":"2018","unstructured":"J.F. Longo, S.M. Weber, B.P. Turner-Ivey, S.L. Carroll, Recent advances in the diagnosis and pathogenesis of neurofibromatosis Type 1 (NF1)-associated peripheral nervous system neoplasms. Adv. Anat. Pathol. 25, 353\u2013368 (2018). https:\/\/doi.org\/10.1097\/PAP.0000000000000197","journal-title":"Adv. Anat. Pathol."},{"key":"819_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s13402-022-00723-3","volume":"45","author":"L-L Ge","year":"2022","unstructured":"L.-L. Ge, M.-Y. Xing, H.-B. Zhang, Q.-F. Li, Z.-C. Wang, Role of nerves in neurofibromatosis type 1-related nervous system tumors. Cell Oncol. (Dordr) 45, 1137\u20131153 (2022). https:\/\/doi.org\/10.1007\/s13402-022-00723-3","journal-title":"Cell Oncol. (Dordr)"},{"key":"819_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13578-021-00586-5","volume":"11","author":"X Jiang","year":"2021","unstructured":"X. Jiang, Y. Li, N. Zhang, Y. Gao, L. Han, S. Li, J. Li, X. Liu, Y. Gong, C. Xie, RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS\/STING signaling pathway in lung adenocarcinoma. Cell Biosci. 11, 74 (2021). https:\/\/doi.org\/10.1186\/s13578-021-00586-5","journal-title":"Cell Biosci."},{"key":"819_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","volume":"19","author":"M Endo","year":"2013","unstructured":"M. Endo, H. Yamamoto, N. Setsu, K. Kohashi, Y. Takahashi, T. Ishii, K.-I. Iida, Y. Matsumoto, M. Hakozaki et al., Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin. Cancer Res. 19, 450\u2013461 (2013). https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1067","journal-title":"Clin. Cancer Res."},{"key":"819_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41698-021-00145-8","volume":"5","author":"S Nagabushan","year":"2021","unstructured":"S. Nagabushan, L.M.S. Lau, P. Barahona, M. Wong, A. Sherstyuk, G.M. Marshall, V. Tyrrell, E.A. Wegner, P.G. Ekert, M.J. Cowley, C. Mayoh, T.N. Trahair, P. Crowe, A. Anazodo, D.S. Ziegler, Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor. NPJ Precis. Oncol. 5, 9 (2021). https:\/\/doi.org\/10.1038\/s41698-021-00145-8","journal-title":"NPJ Precis. Oncol."},{"key":"819_CR35","doi-asserted-by":"publisher","first-page":"19479","DOI":"10.1073\/pnas.0910398106","volume":"106","author":"C Gregorian","year":"2009","unstructured":"C. Gregorian, J. Nakashima, S.M. Dry, P.L. Nghiemphu, K.B. Smith, Y. Ao, J. Dang, G. Lawson, I.K. Mellinghoff, P.S. Mischel, M. Phelps, L.F. Parada, X. Liu, M.V. Sofroniew, F.C. Eilber, H. Wu, PTEN dosage is essential for neurofibroma development and malignant transformation. Proc. Natl. Acad. Sci. U. S. A. 106, 19479\u201319484 (2009). https:\/\/doi.org\/10.1073\/pnas.0910398106","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"819_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pan.2022.03.002","volume":"22","author":"J Shan","year":"2022","unstructured":"J. Shan, Z. Wang, Q. Mo, J. Long, Y. Fan, L. Cheng, T. Zhang, X. Liu, X. Wang, Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K\/AKT\/mTOR pathway. Pancreatology 22, 401\u2013413 (2022). https:\/\/doi.org\/10.1016\/j.pan.2022.03.002","journal-title":"Pancreatology"},{"key":"819_CR37","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.2147\/OTT.S246613","volume":"13","author":"S Zhang","year":"2020","unstructured":"S. Zhang, L. Yan, C. Cui, Z. Wang, J. Wu, A. Lv, M. Zhao, B. Dong, W. Zhang, X. Guan, X. Tian, C. Hao, Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt\/mTOR\/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance. Onco. Targets Ther. 13, 6523\u20136537 (2020). https:\/\/doi.org\/10.2147\/OTT.S246613","journal-title":"Onco. Targets Ther."},{"key":"819_CR38","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1158\/1078-0432.CCR-18-4046","volume":"25","author":"YZ Mazzu","year":"2019","unstructured":"Y.Z. Mazzu, J. Armenia, G. Chakraborty, Y. Yoshikawa, S.A.A. Coggins, S. Nandakumar, T.A. Gerke et al., A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin. Cancer Res. 25, 4480\u20134492 (2019). https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4046","journal-title":"Clin. Cancer Res."},{"key":"819_CR39","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/onc.2014.155","volume":"34","author":"Y Aye","year":"2015","unstructured":"Y. Aye, M. Li, M.J.C. Long, R.S. Weiss, Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene 34, 2011\u20132021 (2015). https:\/\/doi.org\/10.1038\/onc.2014.155","journal-title":"Oncogene"},{"key":"819_CR40","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1517\/14728222.2013.840293","volume":"17","author":"J Shao","year":"2013","unstructured":"J. Shao, X. Liu, L. Zhu, Y. Yen, Targeting ribonucleotide reductase for cancer therapy. Expert Opin. Ther. Targets 17, 1423\u20131437 (2013). https:\/\/doi.org\/10.1517\/14728222.2013.840293","journal-title":"Expert Opin. Ther. Targets"},{"key":"819_CR41","doi-asserted-by":"publisher","first-page":"110996","DOI":"10.1016\/j.biopha.2020.110996","volume":"133","author":"Y Zhan","year":"2021","unstructured":"Y. Zhan, L. Jiang, X. Jin, S. Ying, Z. Wu, L. Wang, W. Yu, J. Tong, L. Zhang, Y. Lou, Y. Qiu, Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed. Pharmacother. 133, 110996 (2021). https:\/\/doi.org\/10.1016\/j.biopha.2020.110996","journal-title":"Biomed. Pharmacother."},{"key":"819_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12943-021-01393-9","volume":"20","author":"S Ohmura","year":"2021","unstructured":"S. Ohmura, A. Marchetto, M.F. Orth, J. Li, S. Jabar, A. Ranft, E. Vinca, K. Ceranski, M.J. Carre\u00f1o-Gonzalez et al., Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol. Cancer 20, 97 (2021). https:\/\/doi.org\/10.1186\/s12943-021-01393-9","journal-title":"Mol. Cancer"},{"key":"819_CR43","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1038\/onc.2017.122","volume":"36","author":"L Dai","year":"2017","unstructured":"L. Dai, Z. Lin, J. Qiao, Y. Chen, E.K. Flemington, Z. Qin, Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Oncogene 36, 5068\u20135074 (2017). https:\/\/doi.org\/10.1038\/onc.2017.122","journal-title":"Oncogene"},{"key":"819_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00280-004-0821-2","volume":"54","author":"Y Yen","year":"2004","unstructured":"Y. Yen, K. Margolin, J. Doroshow, M. Fishman, B. Johnson, C. Clairmont, D. Sullivan, M. Sznol, A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54, 331\u2013342 (2004)","journal-title":"Cancer Chemother Pharmacol"},{"key":"819_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","volume":"130","author":"CA Kunos","year":"2013","unstructured":"C.A. Kunos, T. Radivoyevitch, S. Waggoner, R. Debernardo, K. Zanotti, K. Resnick, N. Fusco, R. Adams, R. Redline, P. Faulhaber, A. Dowlati, Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol. Oncol. 130, 75\u201380 (2013). https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.019","journal-title":"Gynecol. Oncol."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-023-00819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-023-00819-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-023-00819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T19:40:13Z","timestamp":1698781213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-023-00819-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s13402-023-00819-4","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,22]]},"assertion":[{"value":"18 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involving human participants was reviewed and approved by the Ethics Committee of Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine. Informed consent was obtained from patients under institutional review board protocols. The animal study was reviewed and approved by the Ethics Committee of Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"The authors declare no conflicts of interest associated with this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest statement"}}]}}